Biotech Values

[turtlepower]

ARNA - Regarding ARNA's efficacy, one risk for ARNA is that the FDA requests additional efficacy data since the BLOSSOM trial only met 1 of the 3 requirements to satisfy efficacy, ie 5% was more than 35% but not double of placebo (63-35 lorcaserin-placebo) and mean weight loss difference was 4% (<5% requirement).

http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=410040

Edit : I looked at the per-protocol results. The ITT results are slightly better at 47.2 to 25 but barely passes the requirement.